On Thursday, Shares of TASER International, Inc. (NASDAQ:TASR), lost -11.32% to $28.11.
TASER International declared financial results for the second quarter ended June 30, 2015.
“The team at TASER International is executing extremely well across the organization and ongoing to achieve results above our expectations,” said Rick Smith, TASER chief executive officer. “The recently declared acquisitions of Tactical Safety Responses and MediaSolv Solutions are important stepping stones in our long-term strategy to transform TASER and Axon into the premier, global technology provider to law enforcement.”
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs), worldwide. It operates through two segments, TASER Weapons and AXON. The company’s CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system.
Shares of NXP Semiconductors NV (NASDAQ:NXPI), inclined 6.61% to $97.87, during its last trading session.
NXP Semiconductors stated financial results for the second quarter ended July 5, 2015, in addition to offered guidance for the third quarter of 2015.
“Our results in the second quarter of 2015 were very good, as NXP delivered total revenue of $1.51 billion and non-GAAP operating margin of nearly 28 percent. Revenue raised nearly 12 percent from the same period in the preceding year, and raised about three percent from the preceding quarter, in line with our guidance. Non-GAAP diluted earnings per share were $1.44, above the high-end of guidance, and we generated $262 million non-GAAP free cash flow,” said Richard Clemmer, NXP Chief Executive Officer.
NXP Semiconductors N.V., a semiconductor company, provides high performance mixed signal and standard product solutions for radio frequency (RF), analog, power administration, interface, security, and digital processing products worldwide.
Finally, Synthetic Biologics Inc (NYSEMKT:SYN), ended its last trade with -3.63% loss, and closed at $3.19.
Synthetic Biologics intended to release its financial results for the three and six months ended June 30, 2015 on Monday, August 10, 2015, and to host a conference call the same day at 8:30 a.m. EDT.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
